FDA Hikes Fee for Fast-Tracking Tropical Disease Drugs in 2026
Published Date: 9/18/2025
Notice
Summary
The FDA is setting the fee for using a priority review voucher in fiscal year 2026. This affects companies with special drug applications for rare diseases, tropical diseases, or medical threats who want faster reviews. The fee is based on last year’s review costs, so get ready to pay the updated price when you submit your application next year!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
FY2026 Priority Review Voucher Fee
If your company plans to use a Priority Review Voucher in fiscal year 2026, the FDA has set the fee you must pay when you submit a human drug or biological product application. The fee applies to applications using rare pediatric disease, material threat medical countermeasure (MCM), or tropical disease vouchers and is calculated from the difference between FDA's average costs to review priority versus non-priority applications in the previous fiscal year. The notice also outlines the payment procedures you must follow.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16943, International Association of Color Manufacturers; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by the International Association of Color Manufacturers, proposing that we amend our color additive regulations to provide for the safe use of acetone as a solvent in the manufacture of carrot oil. The petition also proposes to add heavy metal limits and secondary names for carrot oil. FDA may also consider other changes to the regulation, as appropriate, during the course of our review.
Previous / Next Documents
Previous: 2025-18074, Sunshine Act Meeting Notice
The U.S. Commission on Civil Rights is holding a public meeting on September 19, 2025, to talk about Latino civil rights and appoint new state advisory members. Anyone interested can join in person in Washington, DC, or watch online for free. This meeting keeps the public in the loop and helps shape important civil rights work without any cost to attendees.
Next: 2025-18076, Sunshine Act Meetings
The SEC and CFTC are teaming up for a public roundtable on September 29, 2025, to talk about making financial rules work better together. This meeting is open to everyone, but seats fill up fast, and you can watch online too. No big costs are involved, but if you want in-person, get there early and register!